Login to Your Account



Revlimid Launching There Now

'Tea'-ing Off in China? Celgene Shares Lessons from Hot Market

By Randy Osborne
Staff Writer

Friday, June 14, 2013
For Celgene Corp., entering Japan proved a relatively brisk venture, said Jerome Zeldis, the company's chief medical officer, but China – where Celgene also has established itself, and is launching Revlimid (lenalidomide) this week – represents something more of a challenge for biotech and pharma firms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription